166 related articles for article (PubMed ID: 36996146)
1. Anti-tumor necrosis factor-alpha monoclonal antibody suppresses colorectal cancer growth in an orthotopic transplant mouse model.
Takasago T; Hayashi R; Ueno Y; Ariyoshi M; Onishi K; Yamashita K; Hiyama Y; Takigawa H; Yuge R; Urabe Y; Oka S; Kitadai Y; Tanaka S
PLoS One; 2023; 18(3):e0283822. PubMed ID: 36996146
[TBL] [Abstract][Full Text] [Related]
2. Vascular-targeted TNFα and IFNγ inhibits orthotopic colorectal tumor growth.
Shen J; Li ZJ; Li LF; Lu L; Xiao ZG; Wu WK; Zhang L; Li MX; Hu W; Chan KM; Cho CH
J Transl Med; 2016 Jun; 14(1):187. PubMed ID: 27342639
[TBL] [Abstract][Full Text] [Related]
3. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
4. Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFα completely prevents breast cancer tumor formation in vivo.
Al-Zoubi M; Salem AF; Martinez-Outschoorn UE; Whitaker-Menezes D; Lamb R; Hulit J; Howell A; Gandara R; Sartini M; Arafat H; Bevilacqua G; Sotgia F; Lisanti MP
Cell Cycle; 2013 Feb; 12(3):480-90. PubMed ID: 23292149
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
[TBL] [Abstract][Full Text] [Related]
6. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
7. A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFα to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil.
Lu L; Li ZJ; Li LF; Shen J; Zhang L; Li MX; Xiao ZG; Wang JH; Cho CH
Peptides; 2017 Nov; 97():54-63. PubMed ID: 28970092
[TBL] [Abstract][Full Text] [Related]
8. Stat6 activity-related Th2 cytokine profile and tumor growth advantage of human colorectal cancer cells in vitro and in vivo.
Li BH; Xu SB; Li F; Zou XG; Saimaiti A; Simayi D; Wang YH; Zhang Y; Yuan J; Zhang WJ
Cell Signal; 2012 Mar; 24(3):718-25. PubMed ID: 22108090
[TBL] [Abstract][Full Text] [Related]
9. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice.
Sugihara T; Okiyama N; Watanabe N; Miyasaka N; Kohsaka H
Arthritis Rheum; 2012 Aug; 64(8):2655-62. PubMed ID: 22392010
[TBL] [Abstract][Full Text] [Related]
11. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model.
Partecke LI; Käding A; Trung DN; Diedrich S; Sendler M; Weiss F; Kühn JP; Mayerle J; Beyer K; von Bernstorff W; Heidecke CD; Keßler W
Oncotarget; 2017 Apr; 8(14):22501-22512. PubMed ID: 28160574
[TBL] [Abstract][Full Text] [Related]
12. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
13. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
Barrera P; Joosten LA; den Broeder AA; van de Putte LB; van Riel PL; van den Berg WB
Ann Rheum Dis; 2001 Jul; 60(7):660-9. PubMed ID: 11406520
[TBL] [Abstract][Full Text] [Related]
14. NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.
Simon PS; Bardhan K; Chen MR; Paschall AV; Lu C; Bollag RJ; Kong FC; Jin J; Kong FM; Waller JL; Pollock RE; Liu K
Oncotarget; 2016 Apr; 7(17):23395-415. PubMed ID: 27014915
[TBL] [Abstract][Full Text] [Related]
15. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
16. Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model.
Yorita N; Yuge R; Takigawa H; Ono A; Kuwai T; Kuraoka K; Kitadai Y; Tanaka S; Chayama K
Cancer Lett; 2021 Feb; 498():111-120. PubMed ID: 33129954
[TBL] [Abstract][Full Text] [Related]
17. PAR2 deficiency enhances myeloid cell-mediated immunosuppression and promotes colitis-associated tumorigenesis.
Ke Z; Wang C; Wu T; Wang W; Yang Y; Dai Y
Cancer Lett; 2020 Jan; 469():437-446. PubMed ID: 31733286
[TBL] [Abstract][Full Text] [Related]
18. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
19. Antibody targeting of claudin-1 as a potential colorectal cancer therapy.
Cherradi S; Ayrolles-Torro A; Vezzo-Vié N; Gueguinou N; Denis V; Combes E; Boissière F; Busson M; Canterel-Thouennon L; Mollevi C; Pugnière M; Bibeau F; Ychou M; Martineau P; Gongora C; Del Rio M
J Exp Clin Cancer Res; 2017 Jun; 36(1):89. PubMed ID: 28659146
[TBL] [Abstract][Full Text] [Related]
20. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.
Devaud C; Westwood JA; John LB; Flynn JK; Paquet-Fifield S; Duong CP; Yong CS; Pegram HJ; Stacker SA; Achen MG; Stewart TJ; Snyder LA; Teng MW; Smyth MJ; Darcy PK; Kershaw MH
Mol Ther; 2014 Jan; 22(1):18-27. PubMed ID: 24048441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
